Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT05152563 is registered in ClinicalTrials.gov with Allakos Inc. as lead sponsor.

NCT NCT05152563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Lead sponsor
Allakos Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
December 31, 2021
Completion date
January 20, 2022
Enrollment
0 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic duodenitis, eosinophilic gastritis